Joseph Turgeon Net Worth

The estimated Net Worth of Joseph W. Turgeon is at least $9.32 Million dollars as of 15 March 2021. Mr. Turgeon owns over 68,334 units of Spectrum Pharmaceuticals stock worth over $581,979 and over the last 11 years he sold SPPI stock worth over $3,036,339. In addition, he makes $5,697,230 as President, Chief Executive Officer, and Director at Spectrum Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Turgeon SPPI stock SEC Form 4 insiders trading

Joseph has made over 17 trades of the Spectrum Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 68,334 units of SPPI stock worth $249,419 on 15 March 2021.

The largest trade he's ever made was selling 162,473 units of Spectrum Pharmaceuticals stock on 18 November 2020 worth over $671,013. On average, Joseph trades about 12,855 units every 26 days since 2013. As of 15 March 2021 he still owns at least 565,028 units of Spectrum Pharmaceuticals stock.

You can see the complete history of Mr. Turgeon stock trades at the bottom of the page.

Joseph Turgeon biography

Joseph W. Turgeon serves as President, Chief Executive Officer, Director of the Company. Mr. Turgeon has served as our President and Chief Executive Officer since December 2017. From April 2014 to December 2017, Mr. Turgeon served as our President and Chief Operating Officer and from October 2012 to April 2014, he served as our Senior Vice President and Chief Commercial Officer. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. (“Amgen”) as Vice President of Sales, where he built and led the sales organization across multiple areas, including oncology, inflammation and bone health.

What is the salary of Joseph Turgeon?

As the President, Chief Executive Officer, and Director of Spectrum Pharmaceuticals, the total compensation of Joseph Turgeon at Spectrum Pharmaceuticals is $5,697,230. There are no executives at Spectrum Pharmaceuticals getting paid more.

How old is Joseph Turgeon?

Joseph Turgeon is 62, he's been the President, Chief Executive Officer, and Director of Spectrum Pharmaceuticals since 2017. There are 7 older and 7 younger executives at Spectrum Pharmaceuticals. The oldest executive at Spectrum Pharmaceuticals, Inc. is Dolatrai Vyas, 76, who is the Independent Director.

What's Joseph Turgeon's mailing address?

Joseph's mailing address filed with the SEC is 11500 S. EASTERN AVENUE, SUITE 240, HENDERSON, NV, 89052.

Insiders trading at Spectrum Pharmaceuticals

Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, and Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.

What does Spectrum Pharmaceuticals do?

spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Complete history of Mr. Turgeon stock trades at Spectrum Pharmaceuticals

Spectrum Pharmaceuticals executives and stock owners

Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Turgeon,
  President, Chief Executive Officer, Director
• Thomas Riga,
  Chief Operating Officer, Chief Commercial Officer, Executive Vice President
• Kurt Gustafson,
  Chief Financial Officer, Executive Vice President
• Keith McGahan,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Francois Lebel,
  Executive Vice President, Chief Medical Officer
• Thomas J. Riga,
  Pres, CEO & Director
• Kurt A. Gustafson,
  Exec. VP & CFO
• Dr. Francois J. Lebel FRCPC, M.D.,
  Exec. VP & Chief Medical Officer
• Keith M. McGahan J.D., L.L.M.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• William Ashton,
  Independent Chairman of the Board
• Bernice Welles,
  Independent Director
• Jeffrey Vacirca,
  Independent Director
• Dolatrai Vyas,
  Independent Director
• Elizabeth Czerepak,
  Independent Director
• Seth Fischer,
  Independent Director
• Lyndah Dreiling,
  Senior Vice President, Clinical Development
• Dr. Lyndah K. Dreiling M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Lisa A. Croissant,
  VP of Sales
• Alberto Dejesus,
  VP of Marketing
• Bimal R. Shah,
  VP of Corp. & Bus. Devel.
• Anthony E Iii Maida,
  Director
• Raymond W Cohen,
  Director
• Stuart Mitchell Krassner,
  Director
• Gilles Gagnon,
  Director
• Luigi Md Lenaz,
  President, Oncology Division
• Juhyun Lim,
  Director
• Jeff L Vacirca,
  Director
• Ann C Phd Kessler,
  Director
• Armin M Kessler,
  Director
• Lee F Md Ph D Allen,
  Chief Medical Officer
• Joseph Kenneth Keller,
  EVP & Chief Operating Officer
• Carol Phd Ocleireacain,
  Director
• Paul H Phd Silverman,
  Director
• Shyam K Kumaria,
  Vice President Finance
• Mark J Glasky,
  Director
• Krishan K Arora,
  Director
• Eric L Phd Nelson,
  Director
• John L Mcmanus,
  VP,Finance, Strategic Planning
• Rajesh C Md Shrotriya,
  Ch, Pres. and Chief Exec. Off.
• Julius A Vida,
  Director
• Dilip J Md Phd Mehta,
  Director
• Richard Fulmer,
  Director
• James Shields,
  Chief Commercial Officer
• Brett L Scott,
  Acting Chief Financial Officer
• Anton Gueth,
  Director
• Mitchell P. Cybulski,
  Director
• George F Tidmarsh,
  CSO AND HEAD OF R&D OPERATIONS
• Nora Brennan,
  See Remarks